Summit Therapeutics Inc. Files 8-K on Shareholder Vote Matters
Ticker: SMMT · Form: 8-K · Filed: Jun 17, 2025 · CIK: 1599298
| Field | Detail |
|---|---|
| Company | Summit Therapeutics Inc. (SMMT) |
| Form Type | 8-K |
| Filed Date | Jun 17, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Summit Therapeutics shareholders voted on key company matters as of June 12, 2025.
AI Summary
Summit Therapeutics Inc. filed an 8-K on June 17, 2025, reporting on matters submitted to a vote of security holders as of June 12, 2025. The filing details corporate actions and decisions made by the company's shareholders.
Why It Matters
This filing informs investors about significant corporate decisions and governance actions that have been voted upon by Summit Therapeutics' shareholders.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of corporate governance actions and does not indicate immediate financial or operational risks.
Key Players & Entities
- Summit Therapeutics Inc. (company) — Registrant
- June 12, 2025 (date) — Date of Earliest Event Reported
- June 17, 2025 (date) — Date of Report
- 601 Brickell Key Drive, Suite 1000, Miami, FL 33131 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on matters submitted to a vote of security holders of Summit Therapeutics Inc.
What is the exact name of the registrant?
The exact name of the registrant is Summit Therapeutics Inc.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on June 12, 2025.
What is the principal executive office address of Summit Therapeutics Inc.?
The principal executive office address is 601 Brickell Key Drive, Suite 1000, Miami, FL 33131.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 17, 2025 regarding Summit Therapeutics Inc. (SMMT).